Latest Mems News

Memphasys Limited secures significant repeat orders from Hamad Medical Corporation, marking a pivotal expansion of its Felix™ system across the MENA region.

Audio Pixels Holdings Limited reported a $7.2 million loss for the half-year ending June 2025, while making significant strides in refining its MEMS digital loudspeaker fabrication process and securing a $6 million loan facility.

Audio Pixels Holdings has locked in a $6 million unsecured loan facility from an investor linked to its chairman, with conversion to notes contingent on shareholder approval and company milestones.

Audio Pixels has validated a major technical milestone for its digital MEMS speaker array and raised $1.25 million through convertible notes, while securing a $6 million funding commitment to support ongoing development amid continued ASX trading suspension.

Memphasys Limited has extended the repayment terms of its convertible notes with major shareholder Peters Investments to mid-2026, reinforcing financial flexibility amid ongoing commercial progress.

Memphasys Limited has completed a $579K shortfall placement, boosting total funds raised to over $1.12 million to support the commercial rollout of its Felix™ System following recent regulatory approvals.

Memphasys has secured CE Mark approval for its Felix™ sperm selection system, enabling full commercial rollout across Europe and activating multi-year contracts worth over A$1.3 million. This milestone signals the company’s transition into a revenue-scaling phase with global growth ambitions.

Audio Pixels has successfully developed an independent MEMS fabrication process for its second-generation digital loudspeaker, overcoming previous manufacturing hurdles and paving the way for scalable production.

Memphasys has inked a five-year supply agreement with Italy’s Centro Fertilita Assistita, marking its first major European contract and setting the stage for broader adoption of its Felix™ sperm isolation system.

Memphasys Limited’s partner International Technical Legacy has placed an early order for 500 Felix™ cartridges ahead of anticipated CE Mark approval, signalling strong clinic demand and validating the company’s direct-selling strategy in the Middle East.

Memphasys Limited has restructured its leadership by eliminating the CEO role to back a direct-selling global commercialisation strategy for its Felix™ System, anticipating imminent CE Mark approval to enter the European IVF market.

Memphasys is intensifying its direct sales efforts for the Felix™ sperm-selection device across key Middle East IVF clinics, positioning for rapid market activation upon CE Mark approval expected early 2026.